References
- Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population - A literature study. J Eur Acad Dermatol Venereol 2013. [Epub ahead of print]
- Zaias N. Onychomycosis. Arch Dermatol 1972;105(2):263-74
- Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol 2012;66(3):494-502
- Welsh O. Onychomycosis. Clin Dermatol 2010;28(2):151-9
- Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1(1):19-26
- Chacon A, Franca K, Fernandez A, Nouri K. Psychosocial impact of onychomycosis: a review. Int J Dermatol 2013;52(11):1300-7
- Baran R. The nail in the elderly. Clin Dermatol 2011;29(1):54-60
- Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139(4):665-71
- Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39(10):746-53
- Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14(6):466-9
- Virgili A, Zampino MR, La Malfa V, et al. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology 1999;199(1):31-4
- Döner N, Yaşar Ş, Ekmekçi TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm 2011;45(3):146-51
- Valeant. Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8% [Internet]. Q www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf
- Medicines and Healthcare products Regulatory Agency. Public Assessment Report Decentralised Procedure Amorolfine 5% W/V Nail Lacquer. 2011. Available from: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con129125.pdf
- Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008;5(11):1267-82
- Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf
- Tosti A, Piraccini BM, Tinea U. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of skin disease. 4th Edition. Elsevier Saunders, Philadelphia, PA, USA; 2014
- Janssen Pharma. SPORANOX® (itraconazole) Capsules [Internet]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf
- Casciano J, Amaya K, Doyle J, et al. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care Langhorne Pa 2003;12(3):47-54
- Shear N, Drake L, Gupta AK, et al. The Implications and Management of Drug Interactions with Itraconazole, Fluconazole and Terbinafine. Dermatology 2000;201(3):196-203
- Penlac, ciclopirox (topical solution 8% w/w). Product monograph. Health Can Prod Drug Data Base Val Can. 2012
- Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4 Suppl):S70-80
- AMYCOR ONYCHOSET, pomade. 1994. Available from: http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=67886607#Presentations
- Friedman-Birnbaum R, Cohen A, Shemer A, et al. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol 1997;36(1):67-9
- Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68(4):600-8
- Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the treatment of onychomycosis: results from two phase 3 studies. 2013. Available from: http://anacor.com/pdf/Tavaborole_Phase%203%20Poster_Final%20Copy_093013.pdf
- Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses 2014. [Epub ahead of print]
- Sigurgeirsson B, Ghannoum M. Therapeutic potential of TDT 067 (terbinafine in Transfersome®): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs 2012;21(10):1549-62
- Wang L, Belisle B, Bassiri M, et al. Chemical characterization and biological properties of NVC-422, a novel, stable N-chlorotaurine analog. Antimicrob Agents Chemother 2011;55(6):2688-92
- Ogura H, Kobayashi H, Nagai K, et al. Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents. Chem Pharm Bull (Tokyo) 1999;47(10):1417-25
- United States Adopted Names Council. Statement on a nonproprietary name adopted by the USAN Council: Efinaconazole. Available from: www.ama-assn.org/resources/doc/usan/efinaconazole.pdf
- Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother 2013;57(5):2405-9
- Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother 2013;57(4):1610-16
- Sugiura K, Hosaka S, Jo W, Tatsumi Y. Unique properties of efinaconazole 10% solution, a new topical treatment for onychomycosis. J Am Acad Dermatol 2013;68(4):AB110
- Bhatt V, Sarpotdar P, Pillai R, Yeh S. Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application. J Am Acad Dermatol 2013;68(4):AB104
- Valeant Canada LP. PrJUBLIATM Efinaconazole Topical Solution, 10% w/w. 2013
- Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol 2013;12(9):1010-16
- Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol 2013;12(2):186-92
- Del Rosso JQ, Reece B, Smith K, Miller T. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthetic Dermatol 2013;6(3):20-4
- Valeant Pharmaceuticals Inc. Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada. 2013. Available from: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Approval-Of-Jublia-For-The-Treatment-Of-Onychomycosis-In-Canada/default.aspx
- Valeant Pharmaceuticals. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole. 2013. Available from: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Receipt-Of-US-FDA-Complete-Response-Letter-For-Efinaconazole/default.aspx
- Gupta AK, Elewski BE, Sugarman JL, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol 2014; In press
- Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatol Treat 2008;19(3):168-75
- Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol 2013;31(5):544-54
- Barber K, Claveau J, Thomas R. Review of treatment for onychomycosis: consideration for special populations. J Cutan Med Surg 2006;10(Suppl 2):S48-53
- Gupta AK, Ryder JE, Lynch LE, Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005;4(3):302-8
- Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010;62(3):411-14
- Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149(Suppl 65):5-9
- Flack M, Robinson P, Ijzerman M, Baker J Jr. Efficacy of topical nanoemulsion (NB-002) for the treatment of distal subungual onychomycosis: a randomized, double-blind, vehicle-controlled trial. Miami Beach, Florida; 2010. Available from: www.nanobio.com/News/documents/2010_AAD_P2108.pdf [ Last accessed 11 April 2013]
- Glaxo-Smith Kline. A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis. 2012. Available from: www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=114554&studyId=4ED3A7C8-ABAF-4DC7-B1A4-362C64C27D09&compound=albaconazole&type=Compound&letterrange=A-F
- Topica Pharmaceuticals. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis - full text view - ClinicalTrials.gov. ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01431820
- Ghannoum MA, Long L, Kim HG, et al. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol 2010;48(3):491-7
- Pinpointe USA. 510(k) Summary K093547. PinPointe FootLaser, Pinpointe USA Inc. 2010. Available from: www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf
- Cutera Inc. 510(k) Summary K103626. GenesisPlus, Cutera Inc. 2011. Available from: www.accessdata.fda.gov/cdrh_docs/pdf10/K103626.pdf
- Light Age Inc. 510(k) Summary K110370. Q-Clear, Light Age. 2011. Available from: www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf
- Alma Lasers. 510(k) Summary K113810. Harmony, Alma Lasers Inc. 2012. Available from: www.accessdata.fda.gov/cdrh_docs/pdf11/K113810.pdf
- Sciton Inc. 510(k) Summary K111483. JOULE ClearSense, Sciton Inc. 2011. Available from: www.accessdata.fda.gov/cdrh_docs/pdf11/K111483.pdf
- Smijs TGM, Mulder AA, Pavel S, et al. Morphological changes of the dermatophyte Trichophyton rubrum after photodynamic treatment: a scanning electron microscopy study. Med Mycol 2008;46(4):315-25
- Smijs TGM, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on Trichophyton rubrum. Photochem Photobiol 2011;87(1):2-13
- A dose-ranging study evaluating the safety and efficacy of IDP-108 in patients with onychomycosis. Available from: www.clinicaltrials.gov/ct2/show/NCT00777868
- Safety and efficacy of topical IDP-108 versus vehicle in patients with onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01008033
- The safety and efficacy of topical IDP-108 versus vehicle in patients with onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01007708